CTS Posts a Record Quarter and Gets Paid Less For It

The best P&L in memory, priced like a peak

CTS delivered the cleanest operating print in its recent history in Q3 2026: sales of $150 million, up 5%, with diversified end markets up 7% and now 60% of the company; a record gross margin of 42.2%, up 330 basis points year over year; adjusted EBITDA margin of 24.7%; and record adjusted diluted EPS of $0.77 against $0.60. Guidance went up, not down — sales to $580–590 million, EPS to $2.78–2.88. “Strong execution drove record profitability and robust cash generation with gross margin of 42.2%, adjusted EBITDA margin of 24.7%, and adjusted diluted EPS of $0.77.” — Pratik Trivedi, Chief Executive Officer · 2026-10-27

And the stock sits 13.3% below its June 22 high of $68.31, with the entire last ninety trading days rendering as one continuous down segment. That divergence is the story of this report. Nothing about the quarter was disappointing. Everything about the quarter was terminal — as in, the kind of margin that invites the question "how much of this repeats?"

Management answered that question before anyone asked it. CFO Ashish Agrawal spent a paragraph dismantling his own beat:

We have an unusually favorable mix, even within the diversified markets, based on the timing of certain projects. We do expect good gross margins in the next few quarters, but maybe not quite at the same level as the 42%.

The 42.2% carried roughly $1.4 million of currency tailwind and an "above normal favorable impact of end market mix driven by timing of certain projects." Strip the FX and the mix accident, and this is a very good margin quarter, not a structural step-change. The gross margin trajectory has been rising for nine years, but the last leg was the sharpest, and sharpest legs mean-revert.

Millar: the flywheel, and its fine print

The quarter's keyword board is not an operating story at all — it is an M&A story. Acquisition of Millar and Millar dominate the fresh language: a ~$30 million-revenue, cash-funded (~$50 million) buy that pushes CTS deeper into medical and into advanced pressure, chemical and electrochemical sensing plus catheter-based technology. It is the logical next stroke of the diversified end market strategy that has been the through-line of every call since 2025 — a strategy whose payoff, as the prior CEO framed it two quarters ago, was always meant to be mix: “with our strategy, we have always said as we grow diversified markets, quality of the earnings will improve, and that is what you are seeing here.” — Kieran O'Sullivan, CEO or President · 2026-04-29

But listen to how carefully Agrawal framed the economics. Gross margin: accretive. EBITDA: “The EBITDA will be positive, obviously, but maybe not quite accretive at the beginning.” — Ashish Agrawal, Chief Financial Officer · 2026-10-27 EPS: accretive in the second half of 2027. That is a deal bought for growth and strategic position, dilutive to near-term margin optics, and analysts knew it — the first two questions were about customer concentration, a keyword that had not previously appeared in this company's disclosure vocabulary. The answer was reassuring (it won't crack the top-customer list) but the question's existence tells you the market is now underwriting integration risk, not just end-market mix.

The transportation "rebound" that management declined to endorse

The most instructive thirty seconds of the Q&A was a pushback. An analyst opened with "really nice to see the rebound in the transportation market" and asked whether it was broad-based. The CEO's answer was a quiet demurral: “the growth in Q3, which was very moderate growth was a combination of some growth in our commercial vehicle segment, but the automotive or the light vehicle market was still pretty much flat to slightly down for the quarter.” — Pratik Trivedi, Chief Executive Officer · 2026-10-27

That matters because transportation is still 40% of sales, and global light vehicle production volumes are guided flat-to-modestly-down on tariff and consumer-demand uncertainty. The cyclical bottom call has been dangling since February, when the then-CEO said plainly of transportation, “we haven't called it bottom. We'd like to get a quarter of data or two behind us.” — Kieran O'Sullivan, CEO · 2026-02-10 Two quarters later, they still aren't calling it.

Meanwhile the smart-actuator saga — the Cummins dual-sourcing question that has appeared in essentially every Q&A for a year — got pushed further into the future. Critical platform approvals land "around the middle of 2027," with revenue a quarter or two behind that. The prior-quarter language on the second-source transition was that visibility would arrive "towards the end of the year." It didn't; it moved. Timing of orders is doing an enormous amount of work across this call — it explains the medical book-to-bill of 0.66, the A&D revenue decline of 7% against a 1.91 book-to-bill, and, implicitly, why investors discount a record quarter.

What the tape is repricing, and the wave CTS is standing in

On the numbers, the market's skepticism is not about leverage or liquidity: effective net cash of $53 million is up sharply year over year, and quarterly free cash flow of roughly $41 million funded the entire Millar cheque without borrowing. Disciplined capital allocation is no longer boilerplate here; it is observable.

The skepticism is about multiple. Price to revenue sits at 3.3x, the highest in the ten-year record and up 36% year over year, even after a 13% drawdown. The shares were re-rated on the diversification narrative before the diversification fully showed up in the income statement — operating margin at 18.5% remains 59% below its 2022Q3 peak.

There is a subtler cross-current worth naming. CTS lists data center applications among its industrial design wins — a genuine adjacency to the AI infrastructure build. But the market's AI data center complex has cooled hard in the near term: the basket is up over the trailing year yet down in the last thirty days across dozens of constituents. CTS is riding a wave that is, at minimum, taking a breather. And unlike several industrial reporters this quarter who booked explicit tariff-refund benefits as margin tailwinds, CTS had no such windfall — its record came from execution and mix, which is a better quality of beat but a less repeatable one.

The setup into Q4 is therefore unusually clean to state and unusually hard to trade: a company executing at the top of its game, buying its way up the value chain into medical sensing, sitting on its strongest balance sheet in three years — and a stock that has already been paid for all of it. Watch three things: whether gross margin normalizes toward 40% or holds the low-40s; whether the medical 0.66 book-to-bill snaps back in Q4 as order timing suggests; and whether Millar's growth gets disclosed with granularity enough to justify a multiple at a decade high. If all three hold, the drawdown is an entry. If the margin's mix tailwind was truly one-time, the tape got there first.